Works matching AU Kang, Yoon-Koo
Results: 142
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
- Published in:
- Journal of Surgical Oncology, 2008, v. 98, n. 1, p. 27, doi. 10.1002/jso.21065
- By:
- Publication type:
- Article
TGF-β-induced cell-cycle arrest through the p21.
- Published in:
- International Journal of Cancer, 1999, v. 83, n. 4, p. 512, doi. 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z
- By:
- Publication type:
- Article
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02383-5
- By:
- Publication type:
- Article
Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2013, v. 9, n. 4, p. 324, doi. 10.1111/ajco.12019
- By:
- Publication type:
- Article
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 2, p. 275, doi. 10.1038/s41416-023-02269-z
- By:
- Publication type:
- Article
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2019, v. 2, n. 8, p. e198243, doi. 10.1001/jamanetworkopen.2019.8243
- By:
- Publication type:
- Article
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE).
- Published in:
- Cancer Medicine, 2023, v. 12, n. 7, p. 7784, doi. 10.1002/cam4.5536
- By:
- Publication type:
- Article
Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 3, p. 1034, doi. 10.1002/cam4.1994
- By:
- Publication type:
- Article
Natural Killer Cells in Human Peripheral Blood and Primary Cutaneous Natural Killer Cell Lymphomas May Express Cutaneous Lymphocyte Antigen.
- Published in:
- Acta Dermato-Venereologica, 2003, v. 83, n. 3, p. 162, doi. 10.1080/00015550310007120
- By:
- Publication type:
- Article
Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1.
- Published in:
- Gastroenterology Research & Practice, 2015, p. 1, doi. 10.1155/2016/6857625
- By:
- Publication type:
- Article
Fine needle aspiration cytology of CD56-positive natural killer/T-cell lymphoma of soft tissue.
- Published in:
- Cancer (0008543X), 2002, v. 96, n. 6, p. 344, doi. 10.1002/cncr.10885
- By:
- Publication type:
- Article
Polymerase chain reaction-based diagnosis of bone marrow involvement in 170 cases of non-Hodgkin lymphoma.
- Published in:
- Cancer (0008543X), 2002, v. 94, n. 12, p. 3073, doi. 10.1002/cncr.10584
- By:
- Publication type:
- Article
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study.
- Published in:
- Oncology, 2013, v. 85, n. 1, p. 44, doi. 10.1159/000350841
- By:
- Publication type:
- Article
A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity.
- Published in:
- Oncology, 2012, v. 82, n. 5, p. 290, doi. 10.1159/000337989
- By:
- Publication type:
- Article
Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer.
- Published in:
- Oncology, 2012, v. 82, n. 2, p. 83, doi. 10.1159/000335959
- By:
- Publication type:
- Article
Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma.
- Published in:
- Oncology, 2012, v. 82, n. 2, p. 119, doi. 10.1159/000336082
- By:
- Publication type:
- Article
Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery.
- Published in:
- Oncology, 2011, v. 80, n. 3/4, p. 208, doi. 10.1159/000328506
- By:
- Publication type:
- Article
PDGFRα Gene Mutation and Protein Expression in Gastrointestinal Stromal Tumors.
- Published in:
- Oncology, 2008, v. 74, n. 1/2, p. 88, doi. 10.1159/000139136
- By:
- Publication type:
- Article
Hand-Foot Syndrome in Patients Treated with Capecitabine-Containing Combination Chemotherapy.
- Published in:
- Journal of Clinical Pharmacology, 2004, v. 44, n. 10, p. 1166, doi. 10.1177/0091270004268321
- By:
- Publication type:
- Article
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 5, p. 995, doi. 10.1002/cncr.34019
- By:
- Publication type:
- Article
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 9, p. 1405, doi. 10.1002/cncr.29220
- By:
- Publication type:
- Article
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 5, p. 1046, doi. 10.1007/s10120-024-01516-3
- By:
- Publication type:
- Article
Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 884, doi. 10.1007/s10120-024-01496-4
- By:
- Publication type:
- Article
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 4, p. 811, doi. 10.1007/s10120-024-01483-9
- By:
- Publication type:
- Article
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 3, p. 439, doi. 10.1007/s10120-024-01484-8
- By:
- Publication type:
- Article
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 3, p. 558, doi. 10.1007/s10120-024-01466-w
- By:
- Publication type:
- Article
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 2, p. 375, doi. 10.1007/s10120-023-01455-5
- By:
- Publication type:
- Article
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial
- Published in:
- Gastric Cancer, 2024, v. 27, n. 1, p. 110, doi. 10.1007/s10120-023-01434-w
- By:
- Publication type:
- Article
Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 1, p. 146, doi. 10.1007/s10120-023-01445-7
- By:
- Publication type:
- Article
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach.
- Published in:
- Gastric Cancer, 2023, v. 26, n. 5, p. 775, doi. 10.1007/s10120-023-01406-0
- By:
- Publication type:
- Article
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.
- Published in:
- Gastric Cancer, 2023, v. 26, n. 4, p. 604, doi. 10.1007/s10120-023-01377-2
- By:
- Publication type:
- Article
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
- Published in:
- Gastric Cancer, 2023, v. 26, n. 1, p. 123, doi. 10.1007/s10120-022-01335-4
- By:
- Publication type:
- Article
Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 6, p. 1039, doi. 10.1007/s10120-022-01325-6
- By:
- Publication type:
- Article
Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 4, p. 794, doi. 10.1007/s10120-022-01298-6
- By:
- Publication type:
- Article
Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 170, doi. 10.1007/s10120-021-01243-z
- By:
- Publication type:
- Article
Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 226, doi. 10.1007/s10120-021-01233-1
- By:
- Publication type:
- Article
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
- Published in:
- Gastric Cancer, 2022, v. 25, n. 1, p. 207, doi. 10.1007/s10120-021-01230-4
- By:
- Publication type:
- Article
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
- Published in:
- Gastric Cancer, 2021, v. 24, n. 1, p. 156, doi. 10.1007/s10120-020-01101-4
- By:
- Publication type:
- Article
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
- Published in:
- Gastric Cancer, 2020, v. 23, n. 1, p. 143, doi. 10.1007/s10120-019-00970-8
- By:
- Publication type:
- Article
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
- Published in:
- Gastric Cancer, 2019, v. 22, n. 4, p. 803, doi. 10.1007/s10120-018-00923-7
- By:
- Publication type:
- Article
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
- Published in:
- Gastric Cancer, 2019, v. 22, n. 4, p. 828, doi. 10.1007/s10120-018-00909-5
- By:
- Publication type:
- Article